Immunohistochemical molecular expression profile of metastatic brain tumor for potent personalized medicine

Recent progress in molecule-targeting therapy may yield personalized therapeutic strategies for patients with metastatic brain tumors (MBT), the most frequently encountered intracranial tumors. For this purpose, we investigated the molecular expression profile of MBT to establish the pathological ba...

Full description

Saved in:
Bibliographic Details
Published in:Brain tumor pathology 2013-07, Vol.30 (3), p.167-174
Main Authors: Kato, Yasutaka, Nishihara, Hiroshi, Yuzawa, Sayaka, Mohri, Hiromi, Kanno, Hiromi, Hatanaka, Yutaka, Kimura, Taichi, Tanino, Mishie, Tanaka, Shinya
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Brain cancer
Breast cancer
Cancer Research
Cancer therapies
Chemotherapy
Drug efficacy
Females
Lung cancer
Medicine
Medicine & Public Health
Metastasis
Neurology
Neurosurgery
Oncology
Original Article
Pathology
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent progress in molecule-targeting therapy may yield personalized therapeutic strategies for patients with metastatic brain tumors (MBT), the most frequently encountered intracranial tumors. For this purpose, we investigated the molecular expression profile of MBT to establish the pathological basis for personalized diagnosis. We studied 166 MBT specimens including 70 cases of lung cancer and 34 cases of breast cancer, and performed immunostaining for EGFR, COX-2, and O -6-methylguanine-DNA methyltransferase (MGMT), among others, which could be target molecules for therapeutic agents or enable prediction of drug efficacy. Loss of MGMT expression was observed in approximately 20–40 % of MBT derived from lung, breast, and gastrointestinal cancers, indicating the possibility of treatment of MBT patients with temozolomide. In addition, MBT expressed a variety of receptor tyrosine kinases, for example EGFR and HER2, and signal transduction molecules, for example phospho-mTOR and COX-2, irrespective of tumor origin, enabling individualized medication with molecule-targeting drugs. We also identified alteration of molecular expression profile in 4 MBT cases during recurrence. Our results not only reveal the molecular characteristics of MBT but also suggest the possibility of potent personalized medicine for MBT patients.
ISSN:1433-7398
1861-387X
DOI:10.1007/s10014-012-0124-y